Industry news

BMJ warns of global impact of Trump on R&D, regulation

Nick Paul Taylor / FierceBiotech

Editors at The BMJ have warned that President Trump’s policies could damage biomedical research and regulation around the world. The journal has committed to fostering open debate and supporting those who “speak truth to power” to counter the actions of an administration it sees as heading for a “head-on collision with the scientific and health communities.”

Top 10 U.S. patent losses of 2017

Eric Sagonowsky / FiercePharma

Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead are each set to hit the patent cliff this year with some of their respective big sellers.

Indian pharmaceutical industry to touch $55 billion in 3 years

GMP News

Indian pharmaceutical market will touch $55 billion by 2020, from the current level of $36.7 billion in 2016, growing at a compound annual growth rate (CAGR) of 15.92%, according to a study jointly conducted by Assocham and research firm Indian Institute of Tourism and Travel Management (IITTM).

More than 20 medicines have been launched to the Russian market

GMP News

The results of project implementation were discussed at the meeting of the general committee of the Presidential Council of the Russian Federation for Economic Modernization and Innovative Development of Russia.

In January 2017 officinal medicines import to Russia amounted 29.8 billion rubles

GMP News

The total cost of finished medicinal products imported in Russia amounted to 29.8 billion rubles in January 2017 (in prices set for release for free circulation). In-bulk supplies for the same period amounted to 6.8 billion rubles. The difference in amount of finished forms as compared to the same period of 2016 is about 20 % (calculated in rubles) — this is the best figure for the last six months.

ICYMI – 3 new reports show dramatic slowdown in medicine spending growth

Holly Campbell / PhRMA

Newly released government actuary and pharmacy benefit manager data confirm previous projections of a significant decline in medicine spending growth. After accounting for discounts and rebates, medicine spending growth in 2016 dipped into the low single digits, with growth rates between 2 and 5 percent.

The future of generic drugs and strategies for commercial success

Pharmalife

GBI Research examines whether the US continue to dominate the global generic drug market. The US continues to be the largest generic drugs market by revenue. Its market is primarily driven by competitive pricing, as pricing is largely decided by companies in the US that take into account market factors (including branded drug price, affordability and market demand for the drug) and government support. Recent estimates show generic drugs save the US $3 billion every week, and unbranded generic drugs accounted for over 80% of prescriptions dispensed in 2013. The low price of generic drugs results in savings for patients, payers and the healthcare system.

The Need for Intelligent IP management

Haydn Evans / Pharmaceutical Executive

Haydn Evans looks at the role of intellectual property (IP) management in protecting pharmaceutical company products. Patents help pharmaceutical companies secure market exclusivity and create greater opportunities for return on investment but the fight for market exclusivity has led to a number of patent challenges.

PhRMA Urges USTR to Ramp Up Patent Enforcement Activities Overseas

Randi Hernandez / BioPharm International

The Office of the United States Trade Representative (USTR), an agency that negotiates with foreign governments to create trade policy agreements, publishes a report each year detailing challenges American innovators face in overseas markets. Pharmaceutical manufacturing trade group PhRMA recently contributed comments to USTR’s 2017 Special 301 Report outlining the specific actions that threaten biopharmaceutical innovation in the United States.

Europe ready to embrace first copies of biotech cancer drugs

Ben Hirschler / Reuters

Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin.